目的探讨口服环戊硫酮对于眼的治疗效果。方法采用前瞻性随机双盲对照研究方法,将2006年12月至2008年8月在厦门大学附属厦门眼科中心眼表疾病专科门诊确诊为干眼的80例患者(80只眼)随机分为两组:口服环戊硫酮组40例、口服维生素C安慰剂对照组40例,各组依评定标准再分为轻度干眼和中重度干眼两个亚组。两组均加用0.05%羧甲基纤维素钠眼液滴眼治疗;分别在治疗前和治疗后3、7、28d各时间点检测并评定患者干眼主观症状、视力、角膜荧光素染色(Fl)、泪膜破裂时间(BUT)及基础泪液分泌试验(SⅠT),治疗前后及两组的各亚组之间均进行重复测量多因素方差分析和样本均数或中位数差值分析。结果除流泪和眼红外,治疗7d后,两组的轻度干眼亚组其他干眼症状、Fl染色、BUT及SⅠT值均较治疗前有所改善。治疗7d后,除流泪和眼红外,仅环戊硫酮组中重度干眼亚组的样本均数差值[0.96(视疲劳)、1.26(干涩感)、0.82(异物感)、1.28(烧灼感)、1.05(畏光)、1.48(疼痛)],以及样本中位数差值[0.30(视力)、4.00(Fl染色)、5.00(BUT)、5.00(SⅠT)],均较治疗前明显改善[F=15.30(视疲劳),15.68(干涩感),13.56(异物感),20.91(烧灼感),18.90(畏光),27.22(疼痛),10.54(视力),188.21(F1染色),261.76(BUT),269.05(SⅠT);均P〈0.05]。在全部28d观察期间内,安慰剂组中重度干眼亚组的样本均数差值[0.10(视疲劳)、0.16(干涩感)、0.09(异物感)、0.38(烧灼感)、0.24(畏光)、0.36(疼痛)、0.23(眼红)],以及样本中位数差值[0.10(视力)、0.50(Fl染色)、0.50(BUT)、0.50(SⅠT)],均较治疗前无明显改善[F=1.76(视疲劳),1.61(干涩感),1.02(异物感),2.3
Objective To investigate anethol trithione therapic efficiency on dry eye. Methods It was a prospective random double-blind controlled study. Eighty cases diagnosed dry eye in Ocular Surface Out-patient Clinic of Xiamen University Affiliated Xiamen Eye Center from 2006 to 2008 were divided into two groups: anethol trithione group and control group, 40 cases in each group. Every group was then divided into two subgroups: weak dry eye subgroup, middle and severe dry eye subgroup. All groups had been added with 0. 05% refresh drops. All patients had been detected and evaluated by subjective symptoms of dry eye, visual acuity,corneal fluorescent staining(Fl), break-up time(BUT) and Schirmer Ⅰ test (SⅠT) at pretherapy and 3,7,28 d of post-therapy. All groups had been compared and analyzed by F test and sample mean difference (SMD) or median difference (MD) comparison between pre-therapy and post-therapy. Results Except of tear and red eye,the other subjective symptoms of dry eye, Fl, BUT and SⅠT of weak dry eye subgroup of both groups had been improved at 7 d after therapy. Only those of middle and severe dry eye subgroup of anethol trithione group had been improved at 7 d after therapy compared with those of pretherapy: SMD = 0. 96 ( visual tiredness ), 1.26 ( dry and unsmooth sensation ), 0. 82 ( foreign body sensation), 1.28 ( burning sensation), 1.05 ( photophobia), 1.48 (pain) ; MD = 0. 30 ( visual acuity) ,4. 00 ( Fl), 5.00 ( BUT), 5.00 ( SⅠT) [ F = 15.30 ( visual tiredness), 15.68 ( dry and unsmooth sensation ), 13.56 ( foreign body sensation ), 20. 91 ( burning sensation ), 18.90 ( photophobia ), 27.22 ( pain ), 10. 54 ( visual acuity), 188.21 (Fl) ,261.76 (BUT) ,269.05 ( SⅠT) ;P 〈 0.05 ]. Those of middle and severe dry eye subgroup of control group hadn't significantly been improved at 28 d after therapy: SMD =0. 10 (visual tiredness) ,0. 16 ( dry and unsmooth sensation) ,0. 09 (